New treatments for lung cancer caused by RIT1 changes
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
['FUNDING_R37'] · FRED HUTCHINSON CANCER CENTER · NIH-11224423
This project aims to find new treatment approaches for people with lung adenocarcinoma driven by RIT1 mutations or RIT1 overexpression.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11224423 on ClinicalTrials.gov |
What this research studies
Researchers are studying how RIT1 mutations and increased RIT1 levels drive lung cancer growth and drug resistance. They will compare RIT1-driven signaling to other RAS-pathway cancers and define how RIT1 interacts with partners like YAP1. The team will use genetic experiments, drug screens, and preclinical lab models including patient-derived samples to test two therapeutic strategies. Findings are intended to guide future targeted therapies for patients with RIT1-altered tumors.
Who could benefit from this research
Good fit: People with lung adenocarcinoma whose tumor testing shows RIT1 mutations, amplification, or high RIT1 expression would be the primary candidates for this research pathway.
Not a fit: Patients without RIT1 alterations or with other lung cancer subtypes are unlikely to receive direct benefit from RIT1-focused strategies.
Why it matters
Potential benefit: If successful, this work could lead to targeted therapies for patients whose tumors are driven by RIT1 alterations and who currently lack specific treatment options.
How similar studies have performed: While targeted drugs have helped other mutation-driven lung cancers, RIT1-directed approaches are novel and have so far shown promise mainly in laboratory and preclinical work rather than completed clinical trials.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERGER, ALICE — FRED HUTCHINSON CANCER CENTER
- Study coordinator: BERGER, ALICE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.